Boehringer Ingelheim International GmbH will take its sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin before the Endocrinologic and Metabolic Drugs Advisory Committee on 13 November in pursuit of a type 1 diabetes indication amid questions from the US Food and Drug Administration about a seemingly small effect size and a potential signal for diabetic ketoacidosis (DKA).
The committee will specifically assess empagliflozin for a supplemental indication as an adjunct to insulin therapy to improve glycemic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?